Clinical trials: Rheumatoid Arthritis (RA)
Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA)
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases
This is an open-label, multi-ascending dose (MAD) phase 1 study, with dose expansion at selected doses, in adult patients with select autoimmune rheumatic diseases including systemic lupus erythematosus (SLE) or rheumatoid…
- Trial name
- NCT06647069
- Testing
- SAR448501
- Where
- 8 sites in Australia, Bosnia and Herzegovina and 3 more
- Volunteers
- 62 people
- Sponsor
- Sanofi
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06978647
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Rheumatoid Arthritis (RA
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
A Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.
- Trial name
- NCT06994143
- Testing
- CLN-978
- Where
- 4 sites in Germany, Italy
- Volunteers
- 37 people
- Sponsor
- Cullinan Therapeutics Inc.
Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA)
Controlling Hyperactive Immunity With Long-lived Lymphocytes
This study is a Phase 1/2, open-label clinical trial to test an experimental treatment called QEL-005 in adults with two autoimmune conditions: diffuse cutaneous systemic sclerosis (dcSSc) and difficult-to-treat rheumatoid…
- Conditions
- Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic Disease
- Trial name
- CHILL (NCT07473154)
- Testing
- QEL-005
- Where
- 10 sites in Germany, Spain and 1 more
- Volunteers
- 16 people
- Sponsor
- Quell Therapeutics Limited
Rheumatoid Arthritis (RA)
A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis
The aim of this study is to evaluate the safety of F8IL10 when administered by intra-articular injection and to determine the maximum tolerated dose (MTD) in order to establish the recommended dose (RD) in patients with Reumatoid…
- Trial name
- DekaJoint (NCT07245992)
- Testing
- F8IL10
- Where
- 2 sites in Italy
- Volunteers
- 54 people
- Sponsor
- Philogen S.p.A.
Rheumatoid Arthritis (RA)
A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis
- Trial name
- NCT06596772
- Testing
- MB04 (proposed biosimilar to etanercept), Enbrel (etanercept)
- Where
- 60 sites in Bulgaria, Georgia and 4 more
- Volunteers
- 501 people
- Sponsor
- mAbxience Research S.L.
Rheumatoid Arthritis (RA)
Probiotics in Adults With Rheumatoid Arthritis
The goal of this clinical study is to collect data on the effect of probiotic administration on clinical outcomes in rheumatoid arthritis patients.
- Trial name
- NCT07304505
- Testing
- Align Extra Strength Probiotic Supplement
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ancilia Biosciences
Rheumatoid Arthritis (RA)
Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis
The goal of this study is to evaluate the safety, pharmacokinetic (PK) characteristics, and preliminary efficacy of a new oral chemical drug in : adults aged 18-70 years (male or female) with moderate to severe active rheumatoid…
- Trial name
- NCT07408024
- Testing
- TollB-001
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Toll Biotech Co. Ltd. (Beijing)
Rheumatoid Arthritis (RA)
A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis
This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase.
- Trial name
- JAB-8263 (NCT07684157)
- Testing
- JAB-8263
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Rheumatoid Arthritis (RA)
TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs
This is a randomized, double-blind, placebo-controlled parallel-group Phase II study. The study aims to evaluate the efficacy and safety of TLL-018 in adult patients with moderate to severe active rheumatoid arthritis who have…
- Trial name
- NCT07748728
- Testing
- TLL-018
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Rheumatoid Arthritis (RA)
At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]
The At-Home ULTRA Study will evaluate performance of the MINI system as indicated for the treatment of adults with active, moderate to severe rheumatoid arthritis who are inadequate responders or are intolerant to conventional…
- Trial name
- At-home ULTRA (NCT07163221)
- Testing
- Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1, Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2, Conventional Synthetic DMARD
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- SecondWave Systems Inc.
Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren's disease
- Trial name
- NCT07048197
- Testing
- Rapcabtagene autoleucel
- Where
- 12 sites in France, Germany and 2 more
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM)
FT839 in Autoimmune Diseases
The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or…
- Conditions
- ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07800871
- Testing
- FT839
- Where
- United States
- Volunteers
- 446 people
- Sponsor
- Fate Therapeutics
Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP)
Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions
This is an open-label, randomized, crossover Phase 1 study to evaluate the bioequivalence, pharmacokinetics, and safety of two oral SKI-O-703 drugs (test and reference) in healthy adults under fed conditions.
- Conditions
- Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP), Rheumatoid Arthritis (RA)
- Trial name
- NCT07675226
- Testing
- SKI-O-703 API in Capsules, SKI-O-703 Formulated Granules in Capsules
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Oscotec Inc.
Rheumatoid Arthritis (RA)
A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)
This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT502 administered subcutaneously to participants with Rheumatoid Arthritis (RA).
- Trial name
- NCT07564154
- Testing
- KT502
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 27 people
- Sponsor
- Kali Therapeutics, Inc.
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs)
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically…
- Conditions
- Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA
- Trial name
- NCT06991114
- Testing
- Allogeneic NK Cells
- Where
- 52 sites in United States, Brazil and 9 more
- Volunteers
- 90 people
- Sponsor
- Artiva Biotherapeutics, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE)
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory autoimmune disease, however not all disease responds or remains in response to CD19 targeted CAR-T cells.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc)
- Trial name
- NCT07729995
- Testing
- LMY-922
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Luminary Therapeutics
Rheumatoid Arthritis (RA)
The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis
The goal of treating patients diagnosed with rheumatoid arthritis (RA) is to achieve remission or low disease activity and thereby prevent joint damage, loss of physical function, and disability.
- Trial name
- NCT03631225
- Testing
- Vectra
- Where
- 30 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Sequenom, Inc.
SLE (Systemic Lupus), RA - Rheumatoid Arthritis
Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA
The goal of this clinical trial is to inform the safety and tolerability of NTR-1011 in treating adult patients diagnosed with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
- Trial name
- LIBERATE-I (NCT07237659)
- Testing
- NTR1011
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Neutrolis
Rheumatoid Arthritis (RA)
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA).
- Trial name
- NCT07258849
- Testing
- LY4213663
- Where
- 10 sites in United States, Germany
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company